Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.

Jason R HealyLori S HartAlexander L ShazadMaria E GagliardiMatthew TsangJimmy EliasJacob B RudenAlvin FarrelJo Lynne RokitaYimei LiAnastasia WyceOlena BarbashVandana BatraMinu SamantaJohn M MarisRobert W Schnepp

Published in: Pediatric blood & cancer (2020)

Combinatorial BET and MEK inhibition was synergistic in the vast majority of neuroblastoma cell lines in the in vitro setting but showed limited antitumor activity in vivo. Collectively, these data do not support clinical development of this combination in high-risk neuroblastoma.

Keyphrases

pi k akt
cancer therapy
signaling pathway
cell proliferation
machine learning